Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Elotuzumab with IMiDs and dex for relapsed/refractory AL amyloidosis shows hematologic response by 3 months in 32%; 4/33 had organ responses; median OS was 37 months and EFS was 11 months.”

“Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement”

Authors: Tobias Dittrich, Timon Hansen, Christoph Kimmich, Kaya Veelken, Anna Jauch, Marc Raab, Carsten Müller-Tidow, Ute Hegenbart, Stefan Schönland.

Myeloma Paper of the Day, April 27th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.